Curriculum Vitae Prof Geoffrey A Pietersz
`
`
`
`
`
`
`
`
`
`
`
`
`
`Curriculum Vitae
`
`
`
`
`
`
`
`
`Prof. Geoffrey A Pietersz, B.Sc. (Hons), Ph.D.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`1
`
`IMMUNOGEN 2135, pg. 1
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`

`
` FAX:
` Email:
`
`Phone:
`
`
`
`(03) 9832 2237
`(03) 9282 2100
`gpietersz@burnet.edu.au
`
`Australian
`
`
`
`
`
`
`
`
`Date of Birth: 28th Aug 1953
`
` Gender: Male
`
`
`
`B.Sc. (Hons), Ph.D.
`
`
`
`
`
`
`
`
`Curriculum Vitae Prof Geoffrey A Pietersz
`SECTION A – PERSONEL INFORMATION
`
`1. Name: Geoffrey A Pietersz
`
`
`
`
`
`
`
`
`
`
`
`2. Citizenship:
`
`
`
`
`3. Academic Qualifications:
`
`
`4. Institution and Department:
`
`5. Current Appointments:
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Bio-Organic & Medicinal Chemistry
`Centre for Biomedical Science
`Burnet Institute
`
`Senior Principal Research Fellow, Burnet Institute
`
`Director, Technology Development, Ascend
`Biopharmaceuticals Ltd
`
`Prof University of Melbourne
`
`Prof Monash University
`
`2
`
`IMMUNOGEN 2135, pg. 2
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`

`Curriculum Vitae Prof Geoffrey A Pietersz
`SECTION B – DETAILED CURRICULUM VITAE
`
`(a) Education:
`
`1975-1977
`
`1978
`
`1979-1982
`
`B.Sc. University of Melbourne
`
`B.Sc. (Hons.) First Class Honours
`
`Completed Ph.D. (Organic Chemistry) at the University of
`Melbourne.
`Thesis title: “Synthesis of Aphid-derived Pyranoquinones”.
`
`Awarded Ph.D.
`
`Dixson Scholarship - Chemistry 3rd year, 1977.
`Merck & Co – novel research into siRNA, 2007.
`
`
`
`1982
`
`Awards:
`
`
` (b) Current appointments:
`
`2006 -present Senior Principal Research Fellow, Burnet Institute
`Professor
`University of Melbourne
`Professor
`Monash University
`Director, Technology Development, Ascend Biopharmaceuticals Ltd
`
`2013-present
`
`
`
`
`(c) Past appointments:
`
`
`1982
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Research Fellow Grade 1
`Research Centre for Cancer and Transplantation
`Department of Pathology
`University of Melbourne
`Parkville, Victoria.
`
`1985
`
`
`
`
`
`Senior Research Officer
`
`
`
`Senior Research Fellow (Level C, Grade 4)
`
`1987-1991
`
`Jun 1991-Dec 1991 Sabbatical Leave, Cell Cytotoxicity Laboratory,
`
`
`
`Austin Research Institute.
`
`1991-1996
`
`
`
`
`
`
`Senior Research Fellow Grade 4
`Austin Research Institute
`Austin Hospital, Studley Rd, Heidelberg, Vic.
`
`
`Oct 1998- Apr 1999 Sabbatical Leave, Biomolecular Research Institute, CSIRO, Clayton,
`Victoria.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Jun 2001-Jun 2003
`
`
`Senior Research Chemist Arthron Ltd
`
`
` 1996-Dec 2004 Principal Research Fellow, Austin Research Institute
`
` 2005 Jan-Dec 2005 Senior Principal Research Fellow, Austin Research Institute
`
`
`3
`
`IMMUNOGEN 2135, pg. 3
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`

`Curriculum Vitae Prof Geoffrey A Pietersz
`
`
`(d) Postgraduate and undergraduate teaching
`
`Ph.D Students
`Current:
`
`2010
`
`
`Completed:
`
`2006
`
`2005
`
`2005
`
`2001
`
`Ms Nicole Brooks (RMIT co-supervisor with Dr Dodie Pouniotis)
`(Did not complete)
`
`Dr Choon Kit Tang (Co-supervisor with Prof Apostolopoulos)
`
`Dr Kuo-Ching Sheng (Co-supervisor with Prof Apostolopoulos)
`
`
`
`
`1999
`
`
`1997
`
`1992
`
`1990
`
`1988
`
`1987
`
`
`Postdoctoral Fellows
`2008 Jun-May 2011
`
`2005- Dec 2010
`
`2007-Jul 2010
`
`2005- Jun 2010
`
`2004 – 2005
`
`2004 – 2006
`
`2002 – 2005
`
`2001 Sep – 2003 Jun
`
`Dr Angela Cendron (Co-supervisor with Prof Mark Hogarth)
`
`Dr John Stambas (Co-supervisor with Dr Christina Cheers, Dept of
`Microbiology, Univ of Melbourne)
`
`Dr Justin Ripper (Co-supervisor with Dr Ian Crosby, Victorian College of
`Pharmacy)
`
`Dr Mark Patrick
`
`Dr Kenia Krauer
`
`Dr Mary Bogdanovsky
`
`
`Prof Mark J Smyth
`
`Dr Jerry Kanellos
`
`
`Dr Jennifer Hsu
`
`Dr Owen Proudfoot
`
`Dr Choon-Kit Tang
`
`Dr Martha Kalkanidis
`
`Dr Martha Kalkanidis (Shared with Dr Magda Plebanski)
`
`Dr Dodie Pouniotis (Shared with Prof Apostolopoulos)
`
`Dr Hilary Vaughan
`
`Dr Gerard Moloney
`
`4
`
`IMMUNOGEN 2135, pg. 4
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`

`Curriculum Vitae Prof Geoffrey A Pietersz
`
`1997 Feb - 1999
`
`1995 Feb - 1998
`
`1994 July - 1995 Sep
`
`1990 Aug. - 1992 June
`
`1987-1989
`
`1988-1989
`
`Visiting Fellows
`
`1992 - 1993
`
`
`1990 (Aug. - Oct.)
`and 1993 (Jan. - Mar.)
`
`1990 (Feb. - Apr.)
`
`B.Med. Sci. Students
`
`2004
`
`Dr Con Panousis
`
`Dr Hilary Vaughan
`
`Dr Julie Atkin
`
`Dr April Rowland
`
`Dr Sarah Andrew
`
`Dr Ada Goerlach
`
`Mr Wenjun Li
`
`
`Dr Roger Melton
`
`
`Dr April Rowland
`
`
`
`Mr. Rene W. Andriessen (Co supervisor, Vrije Universiteit, Faculteit der
`Geneeskunde, Van der Boechorststraat 7, 1081, Amsterdam, The
`Netherlands)
`
`
`
`
`
`
`
`
`2004
`
`1984
`
`1983
`
`B. Sc. (Hons.) Students
`
`
`2003
`
`1990
`
`1988
`
`1988
`
`1984
`
`1983
`
`Work Experience Student
`
`
`Peter J. van Mannen (Co supervisor, as above)
`
`Dr Beth Penington
`
`Dr Grant McArthur (Co supervisor)
`
`Choon Kit Tang (Co-supervisor)
`
`Steve Kotsonis
`
`Sarah Russell
`
`Ricky Johnstone
`
`Mark Smyth
`
`Jerry Kanellos
`
`5
`
`IMMUNOGEN 2135, pg. 5
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`

`Curriculum Vitae Prof Geoffrey A Pietersz
`1992 (Sept. - Mar. 93)
`Ms Colleen Murray
`
` (f) Scientific discipline involvement:
`
`Membership of Societies:
`
`
`
`Editorial Board Membership: Bioconjugate Chemistry (1990-1997)
`
`OncoTargets & Therapy (section editor- Immunotherapy)
`
`Open Veterinary Science Journal
`
`Consultation:
`
`American Chemical Society
`American Association of Cancer Research
`Australian Society of Immunology
`
`
`
`Australian Commercial Research and Development Ltd, Queensland
`Prima Biomed Ltd, Victoria.
`4GVaccines Pty Ltd
`Igavax Pty Ltd
`Avipep Pty Ltd
`Ascend Biopharmaceuticals Pty Ltd
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`SECTION C – RESEARCH SUPPORT
`
`
`6
`
`IMMUNOGEN 2135, pg. 6
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`

`Curriculum Vitae Prof Geoffrey A Pietersz
`Current support:
`
`
`Hogarth, P.M., Pietersz, G.A., Baker, R., Powell M. Fc receptors as targets for the treatment of
`autoimmune inflammation. NHMRC, 2014-2016, $619,890.
`
`Cutts, S. Pigram, P., Pietersz, G.A., Cullinane, C. Tumour-targeted nanoparticles as sensitisers
`for cancer chemotherapy. Cancer Council, Victoria, 2013-2015, $97,000/yr.
`
`
`
`Pietersz, G.A. Mucosal vaccine for Hendra virus. Hendra Virus Urgent Call for Research. 2012-
`2014 (extended to 2015), $94,959/year.
`
`
`Past support:
`
`Pietersz, G. A. and Lewin, S. Targeted activation of latently infected cells: a novel strategy
`towards HIV cure. Australian Centre for HIV and Hepatitis Virology Research (ACH2), 2011-
`2013, $99,000/yr.
`
`Pietersz, G. A. Development of novel anti-arthritic drugs, CASS Foundation, 2012, $50,000.
`
`
`
`
`
`Pietersz, G.A., Apostolopoulos V. Polynucleotide vaccine based on targeted delivery to antigen
`presenting cells. NHMRC project grant, 2008-2010, $159,000/year.
`
`Pietersz, G.A. Novel vaccine formulation for the immunotherapy of adenocarcinomas.
`NHMRC Development grant, 2009, $174,500.
`
`Pietersz, G.A., Barr I. Development of a mannan-based avian influenza vaccine. NHMRC
`Development grant, 2008, $189,000.
`
`Pietersz, G.A. Cell penetrating peptide-mediated delivery of multiple CD8 & CD4 T cell
`epitopes for Breast Cancer vaccines. The Cancer Council of Victoria, 2008-2010, $92346/year.
`
`Pietersz, G.A. Penetratin-Based Vaccines for the Treatment of Breast Cancer. Susan Komen
`Breast Cancer Foundation, USA. 05/06 – 04/08, US$ 120,000/year.
`
`Pietersz, G.A., Barr, I., Hogarth, P. M., Anderson, D. Mucosal vaccine for influenza based on
`inactivated virus and mannan. NHMRC Urgent Research Grant for Research Into a Potential
`Avian Influenza-induced pandemic (365240). 2006, $131,600.
`
`Pietersz, G.A. Aldehyde modified antigens for the immunotherapy of adenocarcinomas.
`NHMRC Project Grant (266818). 2004-2006, 93,500/year.
`
`Pietersz, G.A. Delivery of recombinant MUC1 and CTL epitopes into the cytoplasm of APC
`using a membrane permeable peptide for the immunotherapy of breast cancer. Susan Komen
`Breast Cancer Foundation, USA. 05/04 – 04/06, US$ 95,000/year.
`
`Loveland, B.E, Pietersz, G.A., Apostolopoulos, V., McKenzie, I.F.C. Novel methods of cancer
`antigen uptake for dendritic cells. National Breast Cancer Foundation (Kathleen Cunningham).
`2003-2005, $105,000/year.
`
`Xing, P.X., McKenzie, I.F.C., Pietersz, G.A. Growth inhibitory antibodies in colon cancer.
`Association for International cancer research (UK). 04/03-03/06, 42,749 pounds/year.
`
`7
`
`IMMUNOGEN 2135, pg. 7
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`

`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Curriculum Vitae Prof Geoffrey A Pietersz
`
`Cheers, C., Pietersz, G.A., Coulson, B. Mannan-linked vaccines against mucosal infections.
`NHMRC Development Grant (223324). 06/03-06/04, $150,000.
`
`IFC McKenzie, GA Pietersz and V Apostolopoulos. Vaccine development against novel breast
`cancer antigens, US Army Breast Cancer Grant, Idea Award DAMD17-99-1-9067, August 1999
`– September 2002, US$100/year)
`
`IFC McKenzie, PM Hogarth, M Sandrin, B Loveland and GA Pietersz, Transplantation &
`Cancer Immunology, NH&MRC Program grant – 993215 (1999 $1,267,304; 2000 $1,332,270;
`2001 $ 1,350,239).
`
`
`
`IFC McKenzie, PM Hogarth, M Sandrin, B Loveland and GA Pietersz, Transplantation and
`Tumour Biology, NH&MRC Program grant – 953220 (1995 $1,056,622; 1996 $1,079,007; 1997
`$1,121,044; 1998 $1,145,016).
`
`IFC McKenzie, PM Hogarth and GA Pietersz, Cancer & Inflammation, Research &
`Development Syndicate Grant –July 94- Jun 97 $8.3m.
`
`IFC McKenzie, GA Pietersz, B Loveland, M. Sandrin, Transplantation, Research &
`Development Syndicate Grant –July 95-Jun 96 $12m.
`
`IFC McKenzie et al, Supported by Commonwealth Research Centre of Excellence Grant –1991-
`1994, $870,208.
`
`Supported by Commonwealth Research Centre of Excellence Grant – IFC McKenzie et al, 1982-
`1990, $600,000
`
`
`
`
`
`
`
`Farmitalia Carlo Erba, Milan, Italy – GA Pietersz and IFC McKenzie, 1991-1992, $100,000
`
`Farmitalia Carlo Erba, Milan, Italy – GA Pietersz and IFC McKenzie, 1989-1990, $220,000
`
`GA Pietersz and IFC McKenzie, Drug-monoclonal antibody conjugates for the treatment of
`cancer, Anti-Cancer Council of Victoria –1983-1985, $18,000/year
`
`8
`
`IMMUNOGEN 2135, pg. 8
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`

`Curriculum Vitae Prof Geoffrey A Pietersz
`SECTION D – PUBLICATIONS
`
`Refereed journal articles:
`
`1.
`
`Pietersz, G.A., Merrett, B.K., O’Loughlin, G.J. and Cooke, R.G. Colouring Matters of
`Australian Plants, Part XXIII. A New Synthesis of Arylphenalenones and Naphthoxanthenones.
`Aust. J. Chem., 33:303, 1980.
`
`
`2.
`
`
`3.
`
`
`4.
`
`
`5.
`
`
`6.
`
`
`7.
`
`
`8.
`
`
`9.
`
`
`10.
`
`
`11.
`
`
`12.
`
`Pietersz, G.A., Cameron, D.W. and Feutrill, G.I. Colouring Matters of the Aphidoidea. XLV.
`Synthesis of (±)-Deoxyquinone A Dimethyl Ether and its Epimer (±)-cis-7,9-Dimethoxy-1,3-
`dimethyl-3,4,5,10-tetrahydro-1H-naphtho (2,3-c)pyran-5,10-dione [(±)-7-Methoxyelutherin].
`Aust. J. Chem. 35:1481, 1982.
`
`Stearne, P.A., Pietersz, G.A. and Goding, J.W. cDNA Cloning of the Murine Transferrin
`Receptor: Sequence of Trans-membrane and Adjacent Regions. J. Immunol. 134:3474-3479,
`1985.
`
`Kanellos, J., Pietersz, G.A. and McKenzie, I.F.C. Studies of Methotrexate-Monoclonal
`Antibody Conjugates for Immunotherapy. J. Natl. Cancer Inst. 75:319-331, 1985.
`
`van Driel, I.R., Wilks, A.F., Pietersz, G.A. and Goding, J.W. The Murine Plasma Cell
`Membrane Antigen PC-1: Molecular Cloning of cDNA and Analysis of Expression. Proc. Natl.
`Acad. Sci. USA 82:8619-8623, 1985.
`
`Smyth, M.J., Pietersz, G.A., Classon, B.J. and McKenzie, I.F.C. The Specific Targeting of
`Chlorambucil to Tumours. J. Natl. Cancer Inst. 76:503-510, 1986.
`
`Hogarth, P.M., Hibbs, M.L., Pietersz, G.A., Walker, I.D., Scott, B.M., Bonadonna, L., Deacon,
`N.J. and McKenzie, I.F.C. Use of Monoclonal Antibodies in the Analysis of Cell Membrane
`Antigens and Gene Cloning. Proc. Aust. Biotech. Conference, 116-120, 1986.
`
`Classon, B.J., Murray, B.J., Walker, I.D., Deacon, N.J., Pietersz, G.A., Chambers, G.W.,
`Kirszbaum, L. and McKenzie, I.F.C. Molecular Analysis of Ly-2/3 and L3T4 Molecules.
`Transplant. Proc. 18:287-289, 1986.
`
`Hibbs, M.L., Walker, I.D., Kirszbuam, L., Pietersz, G.A., Deacon, N.D., Chambers, G.W.,
`McKenzie, I.F.C. and Hogarth, P.M. The Murine Fc Receptor for immunoglobulin:
`Purification, Partial Amino Acid Sequence and Isolation of cDNA Clones. Proc. Natl. Acad.
`Sci. USA 83:6980-6984, 1986.
`
`Kanellos, J., Pietersz, G.A., McKenzie, I.F.C., Bonnyman, J. and Baldas, J. Coupling of
`99mTechnitium-Nitrido group to Monoclonal Antibody and use of the Complexes for the
`Detection of Tumors in mice. J. Natl. Cancer Inst. 77:431-439, 1986.
`
`Smyth, M.J., Pietersz, G.A. and McKenzie, I.F.C. Potentiation of In Vitro Cytotoxicity of
`Chlorambucil with Monoclonal Antibodies. J. Immunol 37:3361-3366,1986.
`
`Smyth, M.J., Pietersz, G.A. and McKenzie, I.F.C. Selective Enhancement of Antitumor
`Activity of N-acetyl Melphalan on Conjugation to Monoclonal Antibodies. Cancer Research
`47:62-69, 1987.
`
`9
`
`IMMUNOGEN 2135, pg. 9
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`

`Curriculum Vitae Prof Geoffrey A Pietersz
`13. McKenzie, I.F.C., Smyth, M.J., Cunningham, Z. and Pietersz, G.A. The use of cytotoxic-drug
`antibody immunoconjugates for the treatment of cancer. Proc. 10th International Congress of
`Pharmacol. 1987.
`
`Smyth, M.J., Pietersz, G.A. and McKenzie, I.F.C. The In Vitro and In Vivo Anti-Tumour
`Activity of N-AcMEL-F(ab’)2 Conjugates. Br. J. Cancer 55:7-11, 1987.
`
`Pietersz, G.A., Kanellos, J., Smyth, M.J., Zalcberg, J. and McKenzie, I.F.C. The use of
`monoclonal antibody-conjugates for the diagnosis and treatment of cancer. Immunol. Cell Biol.
`65:111-125, 1987.
`
`Smyth, M.J., Pietersz, G.A. and McKenzie, I.F.C. The Mode of Action of Methotrexate -
`Monoclonal Antibody Conjugates. Immunol. Cell Biol. 65:189-200, 1987.
`
`Smyth, M.J., Pietersz, G.A. and McKenzie, I.F.C. The cellular uptake and cytotoxicity of
`chlorambucil-monoclonal antibody conjugates. Immunol. Cell Biol. 65: 315-321, 1987.
`
`Kanellos, J., Pietersz, G.A., Cunningham, Z. and McKenzie, I.F.C. Anti-tumor activity of
`aminopterin-monoclonal antibody conjugates; in vitro and in vivo comparison with
`methotrexate-monoclonal antibody conjugates. Immunol. Cell Biol. 65:483-493, 1987.
`
`Smyth, M.J., Pietersz, G.A. and McKenzie, I.F.C. Use of vasoactive agents to increase tumor
`perfusion and the antitumor efficacy of drug-monoclonal antibody conjugates. J. Natl. Cancer
`Inst. 79:1367-1373, 1987.
`
`Hogarth, P.M., Hibbs, M.L., Bonadonna, L., Scott, B.M., Witort, E., Pietersz, G.A. and
`McKenzie, I.F.C. The mouse Fc receptor of IgG (Ly-17): molecular cloning and specificity.
`Immunogenetics, 26: 161-168, 1987.
`
`Pietersz, G.A., Kanellos, J. and McKenzie, I.F.C. The Use of Whole Ricin-Antibody
`Conjugates for the Treatment of Tumours in Mice. “Membrane-Mediated Cytotoxicity”, UCLA
`Symposia on Molecular and Cellular Biology, New Series, Volume 45, (EDs) B. Bonavida and
`R.J. Collier. Alan R. Liss, New York, pp 213-223, 1987.
`
`Clark, G.J., Tobias, G.H., Pietersz, G.A., Classon, B.J., Walker, I.D., McKenzie, I.F.C. and
`Deacon, N.J. Isolation of a cDNA clone for the murine CD4 antigen. Transplant. Proc. 20:45-
`58, 1988.
`
`Tjandra, J.J., Pietersz, G.A., Smyth, M.J. and McKenzie, I.F.C. The role of monoclonal
`antibodies (MoAbs) in the therapy of solid tumors. A.N.Z. J. Surg. 58:843-849, 1988.
`
`Pietersz, G.A., Cunningham, Z. and McKenzie, I.F.C. Specific in vitro anti-tumour activity of
`methotrexate-monoclonal antibody conjugates prepared using human serum albumin as an
`intermediary. Immunol. Cell Biol. 66:43-49, 1988.
`
`Pietersz, G.A., Smyth, M.J., Kanellos, J., Cunningham, Z., Sacks, N.P.M. and McKenzie, I.F.C.
`Preclinical and clinical studies with a variety of immunoconjugates. Antib. Immunoconj. and
`Radiopharm. 1:79-103, 1988. (IF=0.943).
`
`Pietersz, G.A., Smyth, M.J. and McKenzie, I.F.C. Immunochemotherapy of a Murine
`Thymoma with Idarubicin - Monoclonal Antibody Conjugates. Cancer Res. 48:926-931, 1988.
`
`10
`
`
`14.
`
`
`15.
`
`
`16.
`
`
`17.
`
`
`18.
`
`
`19.
`
`
`20.
`
`
`21.
`
`
`22.
`
`
`23.
`
`
`24.
`
`
`25.
`
`
`26.
`
`IMMUNOGEN 2135, pg. 10
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`

`Curriculum Vitae Prof Geoffrey A Pietersz
`
`27.
`
`Pietersz, G.A., Kanellos, J. and McKenzie, I.F.C. Novel synthesis and in vitro characterization
`of a disulfide linked ricin-monoclonal antibody conjugates devoid of galactose binding activity.
`Cancer Res. 48:4469-4476, 1988.
`
`
`28.
`
`
`29.
`
`
`30.
`
`
`31.
`
`
`32.
`
`
`33.
`
`
`34.
`
`
`35.
`
`
`36.
`
`
`37.
`
`Choi, C-L., Hudson, P., Stauder, A., Pietersz, G.A. and Brandon, M. The cloning and
`characterization of ovine homeo-box containing genes. Gene, 63:187-197, 1988.
`
`Smyth, M.J., Pietersz, G.A. and McKenzie, I.F.C. “Monoclonal antibody- mediated targeting of
`alkylating agents for the treatment of cancer” in Targeted Diagnosis and Therapy, ed. J.D.
`Rodwell (Marcell Dekker) 1:123-156, 1988.
`
`Pietersz, G.A., Smyth, M.J. and McKenzie, I.F.C. “The use of anthracycline antibody
`complexes for specific anti-tumor therapy” in Targeted Diagnosis and Therapy, ed J.D. Rodwell
`(Marcell Dekker) Vol. 1:25-53, 1988.
`
`Smyth, M.J., Pietersz, G.A. and McKenzie, I.F.C. Immunosuppression of graft rejection
`withIdarubicin-monoclonal antibody conjugates by elimination of T cell subsets in vivo.
`Transplantation 46:126-131, 1988.
`
`Kanellos, J., McKenzie, I.F.C. and Pietersz, G.A. In vivo studies of whole-ricin monoclonal
`antibody conjugates for the treatment of murine tumours. Immunol. Cell Biol. 66:403-415,
`1988.
`
`Smyth, M.J., Pietersz, G.A. and McKenzie, I.F.C. Increased anti-tumor effect of
`immunoconjugates and tumour necrosis factor in vivo. Cancer Res. 48:3607-3612, 1988.
`
`Pietersz, G.A., Smyth, M.J., Tjandra, J.J. and McKenzie, I.F.C. Preclinical and clinical studies
`with N-acetyl melphalan immunoconjugates and tumour necrosis factor. Antib. Immunoconj.
`Radiopharm. 2:47-61, 1989. (IF=0.943).
`
`Tjandra, J.J., Pietersz, G.A., Teh, J.G., Cutherbertson, A.M., Sullivan, J.R., Penfold, C. and
`McKenzie, I.F.C. Phase I clinial trial of drug-monoclonal antibody conjugates in patients with
`advanced colorectal carcinoma - a preliminary report. Surgery, 106:533-545, 1989.
`
`Tjandra, J.J., Sacks, N.P.M., Thompson, C.H., Leyden, M.J., Stacker, S.A., Lichtenstein, M.,
`Russell, I.S., Collins, J.P., Andrews, T.T., Pietersz, G.A. and McKenzie, I.F.C. Monoclonal
`immunoscintigraphy for the detection fo axillary lymph node metastases from breast cancer : A
`prospective study. Br. J. Cancer 59:296-302, 1989.
`
`Smyth, M.J., Pietersz, G.A. and McKenzie, I.F.C. The effect of Idarubicin-monoclonal
`antibody treatment on first-set rejection of murine skin allografts. Transplantation 48:77-79,
`1989.
`
`
`38. Mottram, P.L., Smyth, M.J., Pietersz, G.A., Clunie, G.J.A. and McKenzie, I.F.C. Anti-T cell
`monoclonal antibodies for in vivo treatment of cardiac allograft rejection in mice. Transplant.
`Proc. 21:1020-1021, 1989.
`
`
`39. Mottram, P.L., Smyth, M.J., Pietersz, G.A., Clunie, J.A. and McKenzie, I.F.C. Anti-T cell
`specific immunoconjugates in mice: in vivo effects. Transplant. Proc. 21:3757-3758, 1989.
`
`
`
`11
`
`IMMUNOGEN 2135, pg. 11
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`

`Curriculum Vitae Prof Geoffrey A Pietersz
`Pietersz, G.A., Smyth, M.J. and McKenzie, I.F.C. The use of monoclonal antibodies for
`40.
`immunochemotherapy of cancer. Proc. Aust. Biotech. Conference. 52-55, 1989.
`
`
`41. McKenzie, I.F.C., Smyth, M.J., Mottram, P., Bogdanovski, M. and Pietersz, G.A. Monoclonal
`antibody - drug/toxin immunoconjugates in transplantation. Transplant. Proc. 21:823-825,
`1989.
`
`
`42.
`
`
`43.
`
`Kanellos, J., McKenzie, I.F.C and Pietersz, G.A.. Intratumour therapy of solid tumours with the
`use of ricin-antibody conjugates. Immunol. and Cell Biol. 67:89-99, 1989.
`
`Pietersz, G.A., Smyth, M.J., Kanellos, J., Cunningham, Z. and McKenzie, I.F.C. Preclinical
`studies with immunoconjugates. In Targeted Diagnosis and Therapy, Ed. J.D. Rodwell, Marcell
`Dekker, 2:73-98, 1989.
`
`
`44. McKenzie, I.F.C. and Pietersz, G.A. The use of drug-antibody conjugates for the treatment of
`cancer. Biological Agents in Treatment of Cancer (ed. P. Hersey) 369-375, 1990.
`
`
`45. Mottram, P.L., Pietersz, G.A., Purcell, L.J., Clunie, G.J.A. and McKenzie, I.F.C.
`Immunosuppression by anti-CD8 (Ly-2.1) MAb conjugated to Idarubicin: Studies in the mouse
`heart graft model. Transplant. Proc. 22:2111-2112, 1990.
`
`
`46.
`
`
`47.
`
`
`48.
`
`
`49.
`
`
`50.
`
`
`51.
`
`
`52.
`
`
`53.
`
`
`
`Koulamanda, M., Pietersz, G.A., McKenzie, I.F.C. and Mandel, T.E. Prolongation of fetal
`pancreas allograft survival in mice treated with anti-Il-2 receptor monoclonal antibody (PC61)
`conjugated with Idarubicin. Transplant. Proc. 22:2113-2114, 1990.
`
`Pietersz, G.A., Krauer, K., Toohey B., Smyth, M.J. and McKenzie, I.F.C. Biodistribution of N-
`Acetylmelphalan-Monoclonal antibody conjugates in mice. Antib. Immunoconj. Radiopharm.
`3:27-35, 1990. (IF=0.943).
`
`Johnstone, R.W., Andrew, S.M., Hogarth, P.M., Pietersz, G.A. and McKenzie, I.F.C. The
`effect of temperature on the binding kinetics and equilibrium constants of monoclonal antibodies
`to cell surface antigens. Mol. Immunol. 27:327-333, 1990.
`
`Andrew, S.M., Johnstone, R.W., Russell, S.M., McKenzie, I.F.C. and Pietersz, G.A. A
`comparison of in vitro cell binding characteristics of four monoclonal antibodies and their
`individual tumor localization properties in mice. Cancer Res. 50:4423-4428, 1990.
`
`Pietersz, G.A. The linkage of cytotoxic drugs to monoclonal antibodies for the treatment of
`cancer. Bioconj. Chem. 1:89-95 1990.
`
`Andrew, S.M., Whitehead, R.H., Teh, J-G., Russell, S.M., Johnstone, R.W., McKenzie, I.F.C.
`and Pietersz, G.A. Tumor localization by combinations of monoclonal antibodies in a new
`human colon carcinoma cell line (LIM 1899). Cancer Res. 50:5225-5230, 1990.
`
`Russell, S.M., Krauer, K.G., McKenzie, I.F.C. and Pietersz, G.A. Effect of tumor necrosis
`factor on the antitumor efficacy and toxicity of aminopterin-monoclonal antibody conjugates.
`Parameters in optimization of therapy. Cancer Res. 50:6028-6033, 1990.
`
`Xing, P-X., Reynolds, K., Pietersz, G.A. and I.F.C., McKenzie. Effect of variations in peptide
`sequence on anti-HMFG antibody reactions. Immunol. 72:304-322, 1991.
`
`12
`
`IMMUNOGEN 2135, pg. 12
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`

`Curriculum Vitae Prof Geoffrey A Pietersz
`Smyth, M.J., Bogdanovski, M., McKenzie, I.F.C. and Pietersz, G.A. The antitumour activity of
`54.
`idarubicin-monoclonal antibody conjugates in a disseminated thymoma model. Cancer Res.
`51:310-317, 1991.
`
`
`55.
`
`Goerlach, A., Krauer, K., McKenzie, I.F.C. and Pietersz, G.A. In vitro antitumor activity of 5-
`fluoro-2-deoxyuridine-monoclonal antibody conjugates. Bioconj. Chem. 2:96-101,1991.
`
`
`56. Mottram, P.L., Pietersz, G.A., Purcell, L.J., Clunie, G.J.A. and McKenzie, I.F.C. Deletion of
`graft reactive cells by Ida-anti-CD8 (Ly-2.1) immunoconjugates. Studies in the mouse heart
`graft model. Transplant. Proc. 23:499-500, 1991.
`
`
`57.
`
`
`58.
`
`Krauer, K.G., McKenzie, I.F.C. and Pietersz, G.A. The anti-tumor effect of 2’-deoxy-5’-
`fluorouridine conjugates against a murine thymoma and colon carcinoma xenografts. Cancer.
`Res. 52:132-137, 1992.
`
`Pietersz, G.A. and McKenzie, I.F.C. Antibody conjugates for the treatment of cancer.
`Immunological Reviews 129:57-80, 1992.
`
`
`59. Mottram, P.L., Pietersz, G.A., Purcell, L.J., Krauer, K.G. and McKenzie, I.F.C.
`Immunosuppression by aminopterin or idarubicin conjugated to anti-CD8 (Ly-2.1) in the mouse
`heart allograft model. Transplant. Proc. 24:2301, 1992.
`
`
`60.
`
`
`61.
`
`Pietersz, G.A. and Rowland, A.J. Immunoconjugates for the treatment of cancer. Genetic
`Engineer and biotechnologist. 12:14-18, 1992.
`
`Cameron, D.W., Crosby, I.T. Feutrill, G. I. and Pietersz, G.A. Synthesis of Karwinapthol B, 7-
`methoxy elutherin and ventiloquinone E. Aust. J. Chem. 45:2003-2024, 1992.
`
`
`62. McKenzie, I.F.C. and Pietersz, G.A. Monoclonal antibodies - use in imaging and therapy of
`cancer. Int. J. Gynecol. Cancer 2(1): 19-25, 1992.
`
`
`63.
`
`
`64.
`
`
`65.
`
`
`66.
`
`Pietersz, G.A. and McKenzie, I.F.C. Immunotherapy for Cancer - Toxin - Antibody
`Conjugates. In Toxins and Targets, Eds. D. Walters, M. Lavin, D. Maguire and J. Pearn,
`Harwood academic publishers, p65-74, 1992.
`
`Pietersz, G.A., Krauer, K.G. and McKenzie, I.F.C. The use of monoclonal antibody
`immunoconjugates in cancer therapy. In: “Breast Cancer Therapy and Immunology” Ed: R.L.
`Ceriani. Plenum Press, New York, 169-179. 1993.
`
`Smyth, M.J., Foster, H. McA., Andrew, S.M., Teh, J.G., Krauer, K., McKenzie, I.F.C. and
`Pietersz, G.A. Immunochemotherapy of human colon carcinoma xenografts in nude mice using
`combinations of idarubicin monoclonal antibody conjugates. Immunol. Cell Biol. 71:167-179,
`1993.
`
`Pietersz, G.A. and McKenzie, I.F.C. The use of drug antibody conjugates for the treatment of
`cancer. Cancer Forum 17:116-123,1993.
`
`
`67. Mottram, P.L., Pietersz, G.A., Smyth, M.J., Purcell, L.J., Clunie, G.J.A. and McKenzie, I.F.C.
`An anthracycline-anti CD8 immunoconjugate, Idarubicin-anti-Ly-2.1, prolongs heart allograft
`survival in mice. Transplantation 55:484-490, 1993.
`
`
`
`13
`
`IMMUNOGEN 2135, pg. 13
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`

`Curriculum Vitae Prof Geoffrey A Pietersz
`Krauer, K.G., and Pietersz, G.A. The comparative effects of IL-1 and TNF on AMN-anti-Ly-
`68.
`2.1 immunoconjugate therapy. Biotherapy 6:139-147, 1993.
`
`
`69.
`
`
`70.
`
`
`71.
`
`Krauer, K.G., Bell, R. and Pietersz, G.A. Aminopterin-monoclonal antibody conjugates.
`Antitumor activity and toxicity. Drug Targeting and Delivery 1: 27-33, 1993.
`
`Rowland, A.J., McKenzie, I.F.C. and Pietersz, G.A. Preclinical investigation of the antitumour
`effects of anti-CD-19-idarubicin immunoconjugates. Cancer Immunol. Immunother. 37:195-
`202 1993.
`
`Hancock, W.W., Mottram, P.L., Purcell, L.J., Han, W.R., Pietersz, G.A. and McKenzie, I.F.C.
`Survival of mouse cardiac allografts after CD4 or CD8 monoclonal antibody therapy is
`associated with selective intragraft cytokine protein expression: IL-4 and IL-10 but not IL-2 or
`IFN-ɣ. Transplant. Proc. 25:2937-2938, 1993.
`
`
`72. Mottram, P.L., Purcell, L.J., Pietersz, G.A. and McKenzie, I.F.C. Tolerance induction with
`anti-CD8 monoclonal antibodies in the mouse heart allograft model. Transplant. Proc. 25:2935-
`2936, 1993.
`
`
`73.
`
`
`75.
`
`
`76.
`
`Hancock, W.W., Mottram, P.L., Purcell, L.J., Han, W.R., Pietersz, G.A. and McKenzie, I.F.C.
`Survival of mouse cardiac allografts after CD4 or CD8 monoclonal antibody therapy is
`associated with selective intragraft cytokine protein expression: IL-4 and IL-10 but not IL-2 or
`IFN-(cid:31). Transplant. Proc. 25:2937-2938, 1993.
`
`
`74. Mottram, P.L., Purcell, L.J., Pietersz, G.A. and McKenzie, I.F.C. Tolerance induction with
`anti-CD8 monoclonal antibodies in the mouse heart allograft model. Transplant. Proc. 25:2935-
`2936, 1993.
`
`Rowland, A.J. and Pietersz, G.A. Potentiation of the antitumour activity of N-acetyl melphalan
`antibody conjugates by the vasodilator hydralazine. Drug Targeting and Delivery 1:61-67, 1993.
`
`Pietersz, G.A., Krauer, K., Xu, X.F., McKenzie, I.F.C. and Zalcberg, J.R. Antitumor activity of
`idarubicin-monoclonal antibody conjugate on multidrug resistant cells. Antib. Immunoconj.
`Radiopharm. 6:185-195, 1993.
`
`
`77. Melton, R.G., Rowland, A., Pietersz, G.A., Sherwood, R.F. and McKenzie, I.F.C. Effect of
`tumor necrosis factor on the biodistribution of antibody-carboxypeptidase G2 conjugates in mice
`bearing the E3 thymoma. Eur. J. Cancer. 29A: 8,1177-1183, 1993.
`
`
`78.
`
`
`79.
`
`
`80.
`
`
`
`Sutton, V.R., Burgess, J., Pietersz, G.A., Li, W., McKenzie, I.F.C. and Trapani, J.A. The
`production and preclinical characterisation of a chimeric anti breast cancer antibody, cBC2.
`Therapeutic Immunology, 1:83-93, 1994.
`
`Rowland, A.J., McKenzie, I.F.C. and Pietersz, G.A. Enhanced therapeutic efficacy using a
`cocktail of two antibodies conjugated to different drugs. J. Drug Targeting, 2:113-121, 1994.
`
`Zalcberg, J.R., Pietersz, G.A., Laird, J., Huggins, R., Zimet, A.S., Hennessy, O., McKenzie, A.
`and McKenzie, I.F.C. A Phase I/II study of the intralesional injection of ricin-monoclonal
`antibody conjugates in patients with hepatic metastases from colorectal cancer. Eur. J. Cancer
`30A:1227-1231, 1994.
`
`14
`
`IMMUNOGEN 2135, pg. 14
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`

`Curriculum Vitae Prof Geoffrey A Pietersz
`Rowland, A.J. and Pietersz, G.A. Reduction in the toxicity of AMN-monoclonal antibody
`81.
`conjugates by leucovorin. Cancer Immunol. Immunother., 39:135-139, 1994.
`
`
`82. Mount, P.F., Sutton, V.R., Li, W., Burgess, J., McKenzie, I.F.C., Pietersz, G.A., and Trapani,
`J.A. A chimeric(mouse/human)anti-colon cancer antibody, c30.6, inhibits the growth of human
`colorectal cancer xenografts in SCID mice. Cancer Res., 54:6160-6166, 1994.
`
`
`83.
`
`
`84.
`
`
`85.
`
`Pietersz, G.A. and Krauer, K. Antibody-targeted drugs for the therapy of cancer. J. Drug
`Targeting 2:183-215, 1994.
`
`Pietersz, G.A., Rowland, A., Smyth, M.J. and McKenzie, I.F.C. Chemoimmunoconjugates for
`the treatment of cancer. Adv. Immunol. Vol. 56(Chap 7),301-387, 1994.
`
`Pietersz, G.A. and McKenzie, I.F.C. The genetic engineering of antibody constructs for
`diagnosis and therapy. In Monoclonal antibodies: The second generation., Ed. H. Zola, BIOS
`scientific publishers, Oxford. Chapter 6, 92-116, 1994.
`
`
`
`86. McKenzie, I.F.C. and Pietersz, G.A. Desirable properties of antibodies for therapy. In
`“Targeted Delivery of Imaging Agents” Torchilin, V.P. (ed) CRC Press, Inc. Chap 3. 1995.
`
`
`87.
`
`
`88.
`
`
`89.
`
`
`90.
`
`
`91.
`
`
`92.
`
`
`93.
`
`
`94.
`
`
`
`Pietersz, G.A., Li, W., Sutton, V.R., Burgess, J., McKenzie, I.F.C., Zola, H., and Trapani, J.A.
`In vitro and in vivo antitumour activity of a chimeric anti-CD19 antibody. Cancer Immunol.
`Immunother., 41:53-60, 1995.
`
`Apostolopoulos, V., Pietersz, G.A., Xing, P-X., Lees, C., Michael, M., Bishop, J., and
`McKenzie, I.F.C. The immunogenecity of MUC1 peptides and fusion protein. Cancer Letters,
`90:21-26, 1995.
`
`Apostolopoulos, V., Pietersz, G.A., Loveland, B.E., Sandrin, M.S. and McKenzie, I.F.C.
`Oxidative/Reductive conjugation of mannan to antigen selects for TH1 or TH2 immune
`responses. Proc. Natl. Acad. Sci. USA, 92:10128-10132, 1995.
`
`Apostolopoulos, V., Loveland, B.E., Pietersz, G.A., and McKenzie, I.F.C. Cytotoxic T
`lymphocytes in mice immunised against human MUC1 are MHC restricted. J. Immunol.
`155:5089-5094, 1995.
`
`Apostolopoulos, V., McKenzie, I.F.C. and Pietersz, G.A. Breast cancer immunotherapy:
`Current status and future prospects. Immunol. Cell Biol. 74: 457-464, 1996.
`
`Apostolopoulos, V., Pietersz, G.A. and McKenzie, I.F.C. Cell-mediated immune responses to
`MUC1 fusion protein coupled to mannan. Vaccine 74: 930-938, 1996.
`
`